Methods and systems for evaluating heath/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.

Methods and systems for evaluating health/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's health based on the metabolite levels measured.

Methods and systems for evaluating health/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.

Methods and systems for evaluating heath/disease state of an individual are provided herein. In particular, the disclosure provides methods for measuring levels of one or more metabolites of interest in an individual and using these measurements to assess the individual's health. The disclosure also provides systems for carrying out the disclosed methods. For example, the disclosed systems may include a metabolite level evaluation module to determine the individual's heath based on the metabolite levels measured.

Methods to establish and/or culture a (continuous) cell line of an animal, methods to engineer and/or genetically modify the (continuous) cell line of the animal, methods to isolate collagen from the (continuous) cell line of the animal, methods to modify and/or genetically engineer DNA sequences of collagen for applications and/or to increase the production of the collagen in cells of the animal, and methods to extract collagen from a cultured animal explant through use of a material and/or a process are described herein. In preferred examples, the animal is a jellyfish and the animal explant is a jellyfish explant, a jellyfish polyp explant, a jellyfish medusae explant, or a marine sponge explant.

The present disclosure provides methods to reduce and/or increase the function of the purinergic/Adenosine system in individuals with detected cognitive impairment such as Alzheimer's, Parkinson's, and HIV as well as other diseases with dysregulated ATP secretion and its degradation products including adenosine. The present disclosure provides methods to block the toxic effects of increased circulating levels of ATP observed in several kinds of CNS diseases and maybe peripherical diseases.

Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.

Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the biomarkers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.

In some embodiments, the invention provides tissue-on-a-chip and organ-on-a-chip devices with integrated, on-board photonic integrated circuit optical sensors that allow real-time detection of analytes released from cells disposed on either side of a porous, ultrathin membrane within the device. The invention further provides modular devices for studying cells and interactions between and among cell types. The devices and methods using them are useful for, among other thing, modeling the biological and physiological interactions of cells of different tissue types, allowing high-throughput screening of drug candidates, and informing safety and efficacy in a virtual clinical trial.

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD). The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein.